3rd Annual Recombinant Antibodies (2010) Ts

1,192 views
1,119 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,192
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

3rd Annual Recombinant Antibodies (2010) Ts

  1. 1. 3rd Annual Recombinant Antibodies Examining strategies for increased safety and improved delivery 28th - 29th January 2010, BSG Conference Centre, London, UK BOOK NOW! Key Speakers Dr Kevin Johnson, Chief Executive Officer, PanGenetics Dr Steve Coats, Director of Oncology, Research and Development, MedImmune Dr Jeannick Cizeau, Director, Research, Viventia Biotechnologies Dr Surinder K Sharma, Group Head: ADEPT Biology & Translational Therapeutics, CR-UK Targeting & Imaging Group, UCL Cancer Institute Dr René Hoet, Sr. Director, Research, Genmab Dr Matthew Baker, Chief Scientific Officer, Antitope Philippe Stas, Chief Executive Officer, Algonomics Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics Professor Agamemnon A. Epenetos, Chairman, Trojantec Dr Franck Perez, Research Director, Institut Curie Philip Webber, Partner - Patent Attorney, Frank B. Dehn & Co Marianne Groeneveld, Senior Regulatory Affairs Manager Pharma, TNO Quality of Life Dr Arno Kromminga, Institute for Immunology, Pathology and Molecular Biology, IPM-Biotech Professor Roy Jefferis, Molecular Immunology, The Division of Immunity & Infection, University of Birmingham Dr Yuehua Cong, Research Scientist, PolyTherics Dr Alois B. Lang, Professor of Immunology, Director of Development, GeNeuro Dr Yi Li, Head of Protein Engineering Group, Immunocore Dr Tobias Raum, Senior Director Lead Discovery - Human Antibody Technologies, Micromet Associate Sponsors Junior Sponsor Driving the Industry Forward | www.futurepharmaus.com Organised By Media Partners To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/recombinant
  2. 2. Conference Introduction 3rd Annual Recombinant Antibodies 28th - 29th January 2010, London, UK Recombinant protein technologies are now standard and the Associate Sponsors: current focus has shifted from the method of bulk production to Chiome Bioscience, Inc. is one of the fast growing Japan-based biotech company post-production techniques that promise to enhance stability and founded in 2005 specialized in development of novel antibody and antibody delivery. In the effort to produce orally available therapeutics, generating technology. The ADLib® system has been developed as an innovative formulation issues have become critical. (Source: BCC) and unique platform technology based on cellular library. It is featured by its unrivaled speed to generate antibody and huge diversity of libraries. Chiome Bioscience is offering ADLib® system for research alliance in discovery of lead antibody, co-development of therapeutic antibody, target validation, and technology Dear Colleague, transfer to partners. By leveraging this proprietary technology Chiome Bioscience will make great contributions to pharmaceutical development. dvances in recombinant antibodies have impact on a range of therapy A For further information please visit: www.chiome.jp areas, such as oncology, CNS, infectious and inflammatory diseases. With an Junior Sponsor: expert line-up of speakers, Visiongain’s 3rd Annual Recombinant Antibodies Lonza Custom Manufacturing offers the life sciences market a full range of Conference is an ideal forum for industry and academia alike. This 2-day event bioresearch products, development services and manufacturing for functional and active ingredients. For 30 years we have been helping emerging will explore novel applications of antibodies, recent advances in antibody and established companies increase product quality, improve production processes, navigate the engineering and the latest clinical developments. development and regulatory process, lower the cost of goods, get to market faster, and focus on their core competencies. From early development through launch to commercial leadership and mature market supply, our complete development services, industry-leading manufacturing processes, broad technology By attending this conference you will: platform and lifecycle management experience can help take your product to the next level. For further information please email: www.lonza.com • Examine future trends in global antibody development Media Partners: • ear the latest strategies for protecting antibodies and receive relevant H PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, regulatory information PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. • educe immunogenicity risk by overcoming immune reactions to improve R For further information please email: corporate@pharmiweb.com clinical applications of antibody therapeutics BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to • xplore recent developments in antibody therapy against inflammatory/ E provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission autoimmune diseases was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, • Improve clinical study design publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. • ear case studies on developments of recombinant antibodies as cancer H For further information please visit www.biotechnology-europe.com Future Pharmaceuticals has forged powerful relationships with key industry therapeutics Driving the Industry Forward | www.futurepharmaus.com leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation I look forward to meeting you at the conference strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create Best regards a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. For further information please visit: www.futurepharmaus.com InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com Andrea Charles ‘Pharma Connections Worldwide® is the leading professional business Head of Conferences networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace.‘ For further information please visit: www.pharmaconnections.com Target Audience: • Pharmaceutical and biotechnology companies • Regulatory agencies/ associations / law firms About visiongain: • Contract research and manufacturing organisations (CROs and Visiongain is a specialist business information company focused on providing cutting CMOs) edge products and services across the Pharmaceutical/Biotech, Telecommunications, • Generic companies Defence and Finance sectors, which include reports, conferences, online daily news and • Venture Capitalists offline news analysis and bespoke consultancy. With a commitment to innovation and excellence, visiongain offers flexible solutions to meet our clients’ business intelligence • Academia needs, providing the right information at the right time to facilitate the commercial decision-making process. Our pharmaceutical products include Pharma Business Daily, Who will be there? the leading daily email newsletter for the pharmaceutical, biotech and healthcare • VPs, Directors, Heads and Managers of: industries, and a range of independent, high-quality, in-depth reports covering focused • Research & Development with an interest in protein and peptide and topical areas of concern. Our pharmaceutical conferences address the hottest technology commercial, regulatory and technical topics and provide an ideal forum for debate and networking for pharmaceutical professionals from around the world. • Protein/ Antibody Engineering • Antibody Development For further information, please visit: www.visiongain.com • Antibody Technology • Therapeutic Antibodies • Immunology (Research) Sponsorship and exhibition opportunities: • Immunogenicity • Drug Formulation This event offers a unique opportunity to meet and do business with some • (Clinical) Oncology of the key players in the pharmaceutical and biotech industries. If you have a • Oncology Discovery/ Research service or product to promote, you can do so at this event by: • Oncology Discovery • Hosting a networking drinks reception • Analytical Chemistry • Taking an exhibition space at the conference • Preclinical Development • Advertising in the delegate documentation pack • Clinical Development • Providing branded bags, pens, gifts, etc. • Regulatory Affairs/ IP/ Patents If you would like more information on the range of sponsorship or exhibition • New product development possibilities for visiongain's 3rd Annual Recombinant Antibodies Conference, please • Business Development contact us: • Marketing • Licensing Christopher Clegg, +44 (0)20 7549 9943 christopher.clegg@visiongainglobal.com
  3. 3. Day 1 3rd Annual Recombinant Antibodies Thursday 28th January 2010, London, UK 09:00 Registration and refreshments 13:55 Developments in antibody therapy against 09:30 Opening address from the chair inflammatory/autoimmune diseases • onoclonal antibodies in development for immune and M 09:40 Future trends in antibody development inflammatory diseases • nvolvement of human endogenous retroviral elements (HERVs) I Dr Kevin Johnson in diseases associated with neuroinflammation Chief Executive Officer • herapeutic application targeting pathogenic proteins expressed T PanGenetics by HERVs 10:20 HiPEG™: A novel approach to adapting the • herapeutic potential of humanized antibody targeting HERV-W T envelope in multiple sclerosis: results from a new animal model pharmacokinetics of recombinant antibody fragments Dr Alois B. Lang • olyTherics’ PEGylation strategies for low molecular weight proteins with therapeutic P Professor of Immunology, Director of Development potential GeNeuro • pplication of HiPEG™ to polyhistidine tagged domain antibodies A • etention of biological activity, enhancement of effective half-life R 14:35 Strategies for reducing immunogenicity • Overview of the immunogenicity causes and drivers • owards product development: scale up and stability studies T • ovel EMEA guidance and industry whitepapers applied to antibody therapeutics N Dr Yuehua Cong • educing the immunogenicity risk during early stage and pre-clinical development R Research scientist • Selected case studies PolyTherics Philippe Stas Chief Executive Officer 11:00 Morning refreshments Algonomics 15:15 Reducing risk of clinical immunogenicity • ackground and key drivers leading to clinical immunogenicity B 11:15 Designing quality in antibody development. In silico • ata showing three technologies employed at various stages of the D risk assessment and engineering tools to tackle development pipeline to help optimise pre-clinical decision making aggregation and stability problems • pecific examples where these technologies have been used for the S detection of immunogenicity • Why is aggregation a problem? Stability and aggregation issues during • ata from clinical studies showing incidence of clinical immunogenicity and D the development of antibodies correlation of these observations to immunogenicity testing technologies • When one size does not fit all. Aggregation can appear in many different forms Dr Matthew Baker • Predictive tools to assess aggregation in the computer. Risk assessment Chief Scientific Officer and lead selection ahead of development Antitope • Designing quality in the product to de-risk development. Low 15:55 Afternoon refreshments aggregation, high stability and productivity Dr Jesús Zurdo 16:15 Human immunoglobulin allotypes: possible Head of Advanced Protein Technologies implications for immunogenicity Lonza Biologics • uman IgG subclasses H • uman IgG polymorphism H 11:35 Developing fusion proteins • on-human primate subclasses and polymorphisms N • novel antibody screening approach using an immunotoxin recombinant A • mmunogenicity in animal models and humans I fusion protein format Professor Roy Jefferis • usion proteins are engineered with more favorable design elements over F Molecular Immunology, The Division of Immunity & Infection conventional antibodies making them potentially more efficacious against University of Birmingham s olid cancers 16:55 Latest guidelines for first in human studies for • ifferent anti-EpCAM immunotoxin fusion proteins have been designed D for loco-regional and systemic delivery antibodies and other high risk products • GN 1412: what went wrong? T • linical data to-date has shown the anti-EpCAM fusion proteins to have C • efinition of ‘high risk medicinal product’ D potent activity against solid cancers • tarting dose for phase I: NoAEL or MABEL? S Dr Jeannick Cizeau • uidelines on requirements for ‘first in human’ clinical trials for potential G Director, Research high risk medicinal products Viventia Biotechnologies Dr Leon Hooftman Chief Medical Officer 12.15 Staphylococcal surface display for protein Chroma Therapeutics engineering and epitope mapping 17:35 Generation of unique antibodies with the • he development of a novel technology platform aimed for combinatorial T alternative diversity provided by the ADLib® System protein engineering and epitope mapping of polyclonal and monoclonal • Competitive strength of the ADLib® System antibodies, will be described • Unique strategy for diversifying CDRs • Flexible approach against multi-transmembrane proteins • he surface display of combinatorial libraries of affibody molecules on T • Variety of applications and research collaboration scheme with the Staphylococcus carnosus and subsequent selection of high affinity binders ADLib® System to various target proteins is achieved using flow-cytometric sorting Representative, Chiome Bioscience Dr Stefan Ståhl Professor in Molecular Biotechnology 17:55 Closing remarks from the chair Royal Institute of Technology (KTH), Stockholm, Sweden 18:00 Networking drinks 12:55 Networking lunch Take your discussions further and build new relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2009
  4. 4. Day 2 3rd Annual Recombinant Antibodies Friday 29th January 2010, London, UK 09:00 Registration and refreshments 12:40 Selecting conformation-specific antibodies • Recombinant antibodies use in Cell Biology • Conformation-specific antibodies 09:30 Opening address from the chair • Phospho-specific antibodies Dr David Blakey • Intrabodies Chief Scientist, Oncology Dr Franck Perez AstraZeneca /MedImmune Research Director Institut Curie 09:40 Therapeutic applications for tumor targets 13:20 Networking lunch Dr Steve Coats Director of Oncology Research and Development 14:00 Recombinant antibodies from a regulatory MedImmune perspective: Update on latest guidelines • verview of regulatory requirements for recombinant antibodies; an O update will be presented of applicable EU, US and ICH guidelines 10:20 Enhancing antibody directed therapies • ractical implications of developing recombinant antibodies; what P • oncept to Clinic case studies: C are the consequences of the regulatory requirements in developing recombinant antibodies • ntibody directed enzyme prodrug systems A • onclusions/take home messages C • ntibody based combination therapy A Marianne Groeneveld • ew challenges identified by clinical studies N Senior Regulatory Affairs Manager Pharma • ack to bench to address the challenges B TNO Quality of Life • mproved clinical study design I 14:40 Latest strategies for protecting antibodies Dr Surinder K Sharma • hat are the latest developments in the antibody patent landscape? W Group Head: ADEPT Biology & Translational Therapeutics CR-UK Targeting & Imaging Group • re the Patent Offices’ attitudes to antibody claims changing? A UCL Cancer Institute • re the standards for inventive step being raised? A Philip Webber Partner - Patent Attorney 11:00 Morning refreshments Frank B. Dehn & Co 15:20 Afternoon refreshments 11:20 Human therapeutic antibody discovery and development in oncology 15:40 Set-up and validation of assays for the detection • election of the best therapeutic human antibodies from the Humab S of binding and neutralising antibodies against platform on basis of desired biological specificity various biologicals • herapeutic antibodies acting via multiple modes of action increasing T • isk for the formation of anti-MoAb R the therapeutic efficacy • ifferences between anti-MoAb and ADA against recombinant D • ase studies: Mechanisms of action for two therapeutic antibodies C endogenous proteins • fatumumab (directed against CD20) and daratumumab o • etection of anti-MoAb in the presence of high amounts of MoAb D (directed against CD38) • ellular assays for the detection of NAB against against MoAb C Dr Paul Parren Sr. Dr Arno Kromminga VP Research and Preclinical Development Institute for Immunology, Pathology and Molecular Biology Genmab IPM-Biotech 16:20 Presentation to be announced 12:00 TCR engineering: generation of new therapeutics for Dr Tobias Raum cancer and/or viral infection Senior Director Lead Discovery - Human Antibody Technologies • ationales and advantages of soluble TCR platform technology R Micromet • ritical conditions/requirements for generation of TCR based biologics C • he recent development of soluble TCR T 17:00 Cancer stem cell pathways as therapeutic targets Professor Agamemnon A. Epenetos • he applications of targeting cancer or viral infection using soluble TCR T Chairman Trojantec Dr Yi Li Head of Protein Engineering Group Immunocore 17:40 Chair’s closing remarks and end of conference * Invited
  5. 5. Registration Form 3rd Annual Recombinant Antibodies 28th - 29th January 2010, London, UK Angel For multiple bookings Pentonville Road Photocopy this form Conf. code TS 3rd Annual Recombinant Ci ty Antibodies Ro ad Standard Prices 28th - 29th January 2010 Old Street Conference only Fee: £1299 VAT: £194.85 Total: £1493.85 Location: SG Conference Centre B Old Street Address: 226-236 City Road City Road Promotional Literature Distribution London EC1V 2TT Distribution of your company’s promotional literature to all conference attendees UK Fee: £999 VAT: £149.85 Total: £1148.85 Details How to book Forename: Surname: Email: conferences@visiongainglobal.com Web: http://www.visiongain.com/recombinant Job Title: Company: UK Office: Tel: +44(0) 20 7336 6100 Main Switchboard Number: Fax: +44(0) 20 7549 9932 Visiongain Ltd Address: BSG House 226-236 City Road London EC1V 2QY UK Country: Postcode: General information Venue: Directions: BSG Conference Centre 226 – 236 City Road, London, EC1V 2TT. United Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, Email: http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340 Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the I confirm that I have read and agree to the terms and conditions of booking right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on Methods of payment or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable Payment must be made in sterling to transfer places between conferences and executive briefings. However, if you cannot attend the By Mail: Complete and return your signed registration form together with your cheque payable conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK organisation and are not transferable between countries. By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the to +44 (0) 20 7549 9932 customer by credit card prior to the changes being made. By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or By Bank Transfer: expenses, which may be incurred by the customer as a consequence of the event being postponed or Visiongain Ltd A/C: visiongain Ltd cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses. Barclays Bank Sort Code: 20-71-64 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Piccadilly Branch Account No: 6038 7118 Protection Act 1988. Your personal information contained in this form may be used to update you on 48 Regent Street Swift Code: BARC GB22 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you London, W1B 5RA IBAN: GB80 BARC 20716460387118 wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, Please debit my credit card: EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Access MasterCard Visa American Express Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. Card number: This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain). VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT Expiry Date: incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT. Security number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you. Signature: Unable to attend Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will receive your copy of the event CD Rom two weeks after the event. Yes, please send me a copy of the CD for Price£550 VAT:£82.50 Total:£632.50 News updates Office use only Please tick if you do not want to receive email news updates in the future www.visiongain.com/recombinant

×